Edwards Lifesciences Corporation (EW) Shares Bought by Ontario Teachers Pension Plan Board
Ontario Teachers Pension Plan Board lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 28.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 15,010 shares of the medical research company’s stock after purchasing an additional 3,352 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Edwards Lifesciences Corporation were worth $1,775,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Shine Investment Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences Corporation during the second quarter valued at approximately $126,000. Cornerstone Advisors Inc. increased its holdings in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares in the last quarter. Alexandria Capital LLC increased its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares in the last quarter. Captrust Financial Advisors acquired a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at approximately $149,000. Finally, Johnson Financial Group Inc. increased its holdings in shares of Edwards Lifesciences Corporation by 7.1% in the second quarter. Johnson Financial Group Inc. now owns 1,639 shares of the medical research company’s stock valued at $194,000 after purchasing an additional 109 shares in the last quarter. Institutional investors own 82.08% of the company’s stock.
Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 109.99 on Tuesday. The firm has a market capitalization of $23.23 billion, a P/E ratio of 33.36 and a beta of 0.62. The firm’s 50-day moving average is $112.41 and its 200 day moving average is $110.54. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.
Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same period in the previous year, the firm earned $0.76 earnings per share. The company’s revenue was up 10.9% compared to the same quarter last year. Equities research analysts predict that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.
In related news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $108.86, for a total transaction of $576,958.00. The disclosure for this sale can be found here. Insiders have sold a total of 182,201 shares of company stock worth $20,768,154 over the last 90 days. Company insiders own 2.13% of the company’s stock.
EW has been the topic of a number of recent research reports. BidaskClub lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Canaccord Genuity restated a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a research report on Wednesday, June 7th. Cowen and Company reaffirmed an “outperform” rating and set a $135.00 price target (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation upped their price target on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Seven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Edwards Lifesciences Corporation currently has a consensus rating of “Buy” and a consensus price target of $120.75.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.